Mozart Therapeutics
Calvin Kuo is the Maureen Lyles D’Ambrogio Professor of Medicine (Hematology) at Stanford University School of Medicine. His research focuses on cancer modeling in 3D organoid cultures, biology of intestinal and lung stem cell populations, and molecular regulation of angiogenesis and the blood-brain barrier. He received an A.B., Harvard College, Biochemical Sciences and his M.D./Ph.D., at Stanford University Medical School, with a focus on Cancer Biology. He conducted his residency at Brigham and Women’s Hospital, Internal Medicine, and a Fellowship at Dana-Farber/Partners in Adult Oncology. He is an elected member of the Association of American Physicians, American Society for Clinical Investigation and AAAS.
This person is not in the org chart
This person is not in any offices
Mozart Therapeutics
Mozart Therapeutics is a biotech startup focusing on the development of disease-modifying therapies for autoimmune and inflammatory diseases. The company is using a novel regulatory CD8 T cell network to create disease-modifying CD8 Treg modulators for a variety of autoimmune diseases. Mozart is developing a pipeline of first-in-class 'CD8Treg modulators with the goal of restoring long-term immune balance and preventing the progressive damage caused by an autoreactive and pathogenic immune response.